224 related articles for article (PubMed ID: 26558731)
21. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
Puri R; Libby P; Nissen SE; Wolski K; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Tuzcu EM; Nicholls SJ
Eur Heart J Cardiovasc Imaging; 2014 Apr; 15(4):380-8. PubMed ID: 24448227
[TBL] [Abstract][Full Text] [Related]
22. Effect of two intensive statin regimens on progression of coronary disease.
Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE
N Engl J Med; 2011 Dec; 365(22):2078-87. PubMed ID: 22085316
[TBL] [Abstract][Full Text] [Related]
23. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention.
Ishii H; Nishio M; Takahashi H; Aoyama T; Tanaka M; Toriyama T; Tamaki T; Yoshikawa D; Hayashi M; Amano T; Matsubara T; Murohara T
Clin Ther; 2010 Dec; 32(14):2337-47. PubMed ID: 21353104
[TBL] [Abstract][Full Text] [Related]
24. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study.
Komukai K; Kubo T; Kitabata H; Matsuo Y; Ozaki Y; Takarada S; Okumoto Y; Shiono Y; Orii M; Shimamura K; Ueno S; Yamano T; Tanimoto T; Ino Y; Yamaguchi T; Kumiko H; Tanaka A; Imanishi T; Akagi H; Akasaka T
J Am Coll Cardiol; 2014 Dec; 64(21):2207-17. PubMed ID: 25456755
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent.
Azar M; Valentin E; Badaoui G; Kassab R; Sarkis A; Azar RR
Am J Cardiol; 2011 Jun; 107(11):1571-4. PubMed ID: 21439529
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of follow-up low-density lipoprotein cholesterol level as an independent predictor of changes of coronary atherosclerotic plaque size as determined by intravascular ultrasound analysis after statin (atorvastatin or simvastatin) therapy.
Hong MK; Lee CW; Kim YH; Park DW; Lee SW; Park CB; Jang JS; Han KH; Cheong SS; Kim JJ; Park SW; Park SJ
Am J Cardiol; 2006 Oct; 98(7):866-70. PubMed ID: 16996864
[TBL] [Abstract][Full Text] [Related]
27. Effects of Atorvastatin Dose and Concomitant Use of Angiotensin-Converting Enzyme Inhibitors on Renal Function Changes over Time in Patients with Stable Coronary Artery Disease: A Prospective Observational Study.
Wieczorek-Surdacka E; Świerszcz J; Surdacki A
Int J Mol Sci; 2016 Feb; 17(2):. PubMed ID: 26848655
[TBL] [Abstract][Full Text] [Related]
28. Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial.
Dirajlal-Fargo S; Kinley B; Jiang Y; Longenecker CT; Hileman CO; Debanne S; McComsey GA
AIDS; 2015 Jan; 29(3):313-21. PubMed ID: 25686680
[TBL] [Abstract][Full Text] [Related]
29. Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome.
Rodés-Cabau J; Tardif JC; Cossette M; Bertrand OF; Ibrahim R; Larose E; Grégoire J; L'allier PL; Guertin MC
Am J Cardiol; 2009 Sep; 104(6):750-7. PubMed ID: 19733706
[TBL] [Abstract][Full Text] [Related]
30. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects.
Schaefer EJ; McNamara JR; Asztalos BF; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2005 May; 95(9):1025-32. PubMed ID: 15842965
[TBL] [Abstract][Full Text] [Related]
31. Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease.
Bliden KP; Chaudhary R; Lopez LR; Damrongwatanasuk R; Guyer K; Gesheff MG; Franzese CJ; Kaza H; Tantry US; Gurbel PA
Am J Cardiol; 2016 Sep; 118(5):673-8. PubMed ID: 27401271
[TBL] [Abstract][Full Text] [Related]
32. Subclinical myocyte injury, fibrosis and strain in relationship to coronary plaque in asymptomatic HIV-infected individuals.
Fitch KV; DeFilippi C; Christenson R; Srinivasa S; Lee H; Lo J; Lu MT; Wong K; Petrow E; Sanchez L; Looby SE; Hoffmann U; Zanni M; Grinspoon SK
AIDS; 2016 Sep; 30(14):2205-14. PubMed ID: 27314177
[TBL] [Abstract][Full Text] [Related]
33. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia.
van Tits LJ; Smilde TJ; van Wissen S; de Graaf J; Kastelein JJ; Stalenhoef AF
J Investig Med; 2004 Apr; 52(3):177-84. PubMed ID: 15222407
[TBL] [Abstract][Full Text] [Related]
34. Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment.
Papathanasiou AI; Lourida ES; Tsironis LD; Goudevenos JA; Tselepis AD
Atherosclerosis; 2008 Jan; 196(1):289-297. PubMed ID: 17140582
[TBL] [Abstract][Full Text] [Related]
35. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.
Hoffmann U; Lu MT; Olalere D; Adami EC; Osborne MT; Ivanov A; Aluru JS; Lee S; Arifovic N; Overton ET; Fichtenbaum CJ; Aberg JA; Alston-Smith B; Klingman KL; Waclawiw M; Burdo TH; Williams KC; Zanni MV; Desvigne-Nickens P; Cooper-Arnold K; Fitch KV; Ribaudo H; Douglas PS; Grinspoon SK;
Am Heart J; 2019 Jun; 212():1-12. PubMed ID: 30928823
[TBL] [Abstract][Full Text] [Related]
36. Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease.
Ndrepepa G; Braun S; von Beckerath N; Mehilli J; Gorchakova O; Vogt W; Schömig A; Kastrati A
Clin Chim Acta; 2005 Oct; 360(1-2):178-86. PubMed ID: 15993392
[TBL] [Abstract][Full Text] [Related]
37. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
38. Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype.
Xu RX; Guo YL; Li XL; Li S; Li JJ
Clin Exp Pharmacol Physiol; 2014 Jul; 41(7):475-81. PubMed ID: 24739131
[TBL] [Abstract][Full Text] [Related]
39. Polygenic Scores and Preclinical Cardiovascular Disease in Individuals With HIV: Insights From the REPRIEVE Trial.
Zou RS; Ruan Y; Truong B; Bhattacharya R; Lu MT; Karády J; Bernardo R; Finneran P; Hornsby W; Fitch KV; Ribaudo HJ; Zanni MV; Douglas PS; Grinspoon SK; Patel AP; Natarajan P
J Am Heart Assoc; 2024 Apr; 13(7):e033413. PubMed ID: 38533953
[TBL] [Abstract][Full Text] [Related]
40. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.
Joy MS; Dornbrook-Lavender KA; Chin H; Hogan SL; Denu-Ciocca C
Ann Pharmacother; 2008 Jan; 42(1):9-15. PubMed ID: 18000162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
